Skip to content

Prognosis of Veno-Venous Extracorporeal Membrane Oxygenation in Emergency Thoracic Surgery

Prognostic Factors for 90-day Mortality in Patients Undergoing Veno-venous Extracorporeal Membrane Oxygenation for Emergency Thoracic Surgery

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07016685
Acronym
PECUR
Enrollment
380
Registered
2025-06-12
Start date
2025-06-01
Completion date
2026-04-30
Last updated
2025-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, ECMO Outcomes, Emergency Surgery, Mortality, Propensity Score Matching, Retrospective Cohort, Thoracic Surgery, VV-ECMO

Keywords

thoracic surgery, VV-ECMO, emergency surgery, ARDS, retrospective cohort, propensity score matching, mortality, ECMO outcomes

Brief summary

Veno-vneous extracorporeal membrane oxygenation (VV-ECMO) is an established support strategy for acute respiratory failure, but its role in the perioperative management of emergency thoracic surgery remains poorly defined. This retrospective, multicenter, observational study aims to assess the clinical outcomes and prognostic factors in this high-risk population. Patients undergoing emergency thoracic procedures requiring VV-ECMO will be compared to a control cohort of patients treated with VV-ECMO for medical respiratory failure. Data will be collected from two French academic centers (CHU Amiens-Picardie and CHU Dijon).

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire Dijon
CollaboratorOTHER
Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults ≥ 18 years * VV-ECMO initiated during or after emergency thoracic surgery * No opposition to data use

Exclusion criteria

* Pregnant women * Veno-Arterial ECMO patients * Patients under legal protection

Design outcomes

Primary

MeasureTime frame
90-day all-cause mortality90 days

Secondary

MeasureTime frameDescription
90-day mortality in oncologic vs. non-oncologic thoracic surgery90 days
Postoperative complication rates90 daysPostoperative complication rates (hemorrhagic, thrombotic, infectious)

Countries

France

Contacts

Primary ContactChristophe Beyls, MD
beyls.christophe@chu-amiens.fr33+3 22 08 78

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026